GLP-1 Weight Loss Statistics 2026
Data-driven insights on GLP-1 weight loss medications, clinical trial outcomes, obesity in the US, and the rise of online telehealth programs.
42%
of US adults live with obesity
Source: CDC, 2026 update
14.9%
average weight loss with semaglutide 2.4 mg over 68 weeks (STEP-1)
Source: Wilding et al., NEJM 2021
22.5%
average weight loss with tirzepatide 15 mg over 72 weeks (SURMOUNT-1)
Source: Jastreboff et al., NEJM 2023
55.6%
of patients on tirzepatide lost at least 20% of body weight
Source: SURMOUNT-1 data
20%
reduction in major cardiovascular events with semaglutide (SELECT trial)
Source: Lineaweaver et al., NEJM 2024
62.8%
reduction in sleep apnea severity with tirzepatide (SURMOUNT-OSA)
Source: Malhotra et al., 2024
$1,349
monthly list price for Wegovy without insurance
Source: Novo Nordisk, 2026
$249-399
monthly cost for compounded semaglutide via telehealth
Source: Telehealth pricing, 2026
35%
of GLP-1 prescriptions in 2026 are filled via telehealth or compounded programs
Source: Industry estimates, 2026
28.7%
weight loss with retatrutide in Phase 3 trials (highest of any GLP-1)
Source: TRIUMPH-3, 2025
22.7%
weight loss with CagriSema (semaglutide + cagrilintide)
Source: REDEFINE-1, 2025
51%
of SURMOUNT-OSA participants achieved sleep apnea resolution with tirzepatide
Source: SURMOUNT-OSA, 2024
Why GLP-1s matter in 2026
GLP-1 receptor agonists have become the most effective prescription option for chronic weight management. They are reshaping how US adults treat obesity, with telehealth making access easier than ever.
Clinical trial snapshot
- STEP-1: Semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks vs 2.4% with placebo.
- SURMOUNT-1: Tirzepatide 15 mg produced 20.9% mean weight loss at 72 weeks, with 55.6% of patients losing ≥20%.
- SURMOUNT-OSA: Tirzepatide reduced sleep apnea severity by 62.8% in adults with obesity.
- SELECT: Semaglutide reduced major cardiovascular events by 20% in adults with overweight or obesity and heart disease.
Cost and access
Brand-name medications remain expensive, while compounded and telehealth programs have expanded access for uninsured and underinsured Americans.
Start a GLP-1 program online
Check your eligibility, get approved by a US-licensed provider, and have medication shipped to your door.
Check my eligibilityMethodology
Statistics are sourced from peer-reviewed clinical trials, FDA labels, CDC obesity data, and published pharmacy pricing. We update this page as new data becomes available.
This page is for educational purposes. Always consult a healthcare provider for personal medical advice. Affiliate links are disclosed.